2INV Stock Overview
2invest AG, an investment company, acquires, holds, manages, and sells investments in corporations and partnerships primarily in the biotechnology, life science, and IT sectors in Germany and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||€11.30|
|52 Week High||€13.46|
|52 Week Low||€10.40|
|1 Month Change||2.73%|
|3 Month Change||-11.02%|
|1 Year Change||-9.60%|
|3 Year Change||36.77%|
|5 Year Change||-30.17%|
|Change since IPO||-67.41%|
Recent News & Updates
|2INV||DE Biotechs||DE Market|
Return vs Industry: 2INV exceeded the German Biotechs industry which returned -31.6% over the past year.
Return vs Market: 2INV exceeded the German Market which returned -13.3% over the past year.
|2INV Average Weekly Movement||3.1%|
|Biotechs Industry Average Movement||8.2%|
|Market Average Movement||6.3%|
|10% most volatile stocks in DE Market||10.7%|
|10% least volatile stocks in DE Market||3.5%|
Stable Share Price: 2INV is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 2INV's weekly volatility (3%) has been stable over the past year.
About the Company
2invest AG, an investment company, acquires, holds, manages, and sells investments in corporations and partnerships primarily in the biotechnology, life science, and IT sectors in Germany and internationally. The company was formerly known as 4basebio AG and changed its name to 2invest AG in January 2021. 2invest AG is based in Heidelberg, Germany.
2invest Fundamentals Summary
|2INV fundamental statistics|
Is 2INV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2INV income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.33|
|Net Profit Margin||-94.83%|
How did 2INV perform over the long term?See historical performance and comparison
Is 2invest undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 2INV's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2INV's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 2INV is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: 2INV is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2INV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2INV is good value based on its PB Ratio (0.8x) compared to the DE Biotechs industry average (1.5x).
How is 2invest forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2INV's forecast earnings growth is above the savings rate (-0.05%).
Earnings vs Market: Insufficient data to determine if 2INV's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 2INV's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 2INV's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2INV's Return on Equity is forecast to be high in 3 years time
How has 2invest performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2INV is currently unprofitable.
Growing Profit Margin: 2INV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2INV is unprofitable, but has reduced losses over the past 5 years at a rate of 36.3% per year.
Accelerating Growth: Unable to compare 2INV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2INV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: 2INV has a negative Return on Equity (-2.29%), as it is currently unprofitable.
How is 2invest's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 2INV's short term assets (€71.8M) exceed its short term liabilities (€4.5M).
Long Term Liabilities: 2INV's short term assets (€71.8M) exceed its long term liabilities (€266.0K).
Debt to Equity History and Analysis
Debt Level: 2INV has more cash than its total debt.
Reducing Debt: 2INV's debt to equity ratio has reduced from 8.6% to 5.1% over the past 5 years.
Debt Coverage: 2INV's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 2INV earns more interest than it pays, so coverage of interest payments is not a concern.
What is 2invest current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2INV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2INV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2INV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2INV's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2INV has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
2invest has no CEO, or we have no data on them.
Experienced Management: 2INV's management team is seasoned and experienced (5.8 years average tenure).
Experienced Board: 2INV's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
2invest AG's employee growth, exchange listings and data sources
- Name: 2invest AG
- Ticker: 2INV
- Exchange: XTRA
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €64.954m
- Shares outstanding: 5.75m
- Website: https://2invest-ag.com
Number of Employees
- 2invest AG
- Ziegelhäuser Landstr. 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/20 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.